Stock Ratings / Health Care / NEUP / financials

MRKR (48) RADX (61) JAGX (31) AEON (48) ⌘ Pro Terminal →

Neuphoria Therapeutics Inc. (NEUP) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Q: How profitable is Neuphoria Therapeutics Inc. (NEUP)?

In FY 2025 (10-K), NEUP converted $15.6M of revenue into a 52% gross margin, 0% operating margin, and $77229 in free cash flow (0.5% FCF margin).

$3.06 -8.93% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Neuphoria Therapeutics Inc. (NEUP) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $16.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-11.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NEUP)Realized 20D OHLCV Swing Band: ±7.7%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How NEUP Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$77.2K (0.5% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $15.6M

FY24

Rev $15.6M

FY25

Rev $15.6M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$15.6M	52%	-7.2%	-$369.6K	$77.2K	-11.8%
FY 2024	$15.6M	52%	-114.3%	-$15.5M	-$14.7M	-45%
FY 2023	$15.6M	52%	-140.5%	-$21.4M	-$14.6M	-11.8%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NEUP)

✓Walkthrough of NEUP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NEUP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -41.94%🛡️ HOLDING TREND SUPPORT

2026-10-30O $3.10H $3.11L $3.04C $3.06VOL 70.2K

RES: $3.51SUP: $3.06SMA50: $3.57SMA200: $4.16

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NEUP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NEUP Butterfly Map → + Track NEUP →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NEUP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NEUP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NEUP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NEUP)

Health Care Rank #899 of 1016 ⚔️ MRKR vs NEUP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NEUP vs. MRKR, RADX, JAGX, AEON)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Neuphoria Therapeutics Inc. (NEUP) ranks #899 by composite RQD confidence (32/100, grade E) and #849 by equity capitalization ($16.6M). Within this direct 5-issuer industry benchmark cohort, NEUP leads on earnings valuation at N/A trailing P/E, while NEUP leads on capital efficiency and profitability with -11.8% ROIC and — gross margin. RADX currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with NEUP at 32/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NEUP ACTIVE Neuphoria Therapeutics Inc.	E	32/100	—	—	-11.8%	-8.93%	$16.6M	Benchmark Subject
MRKR Marker Therapeutics Inc.	D	48/100	—	—	-35.0%	+1.00%	$16.8M	/mrkr-vs-neup →
RADX Radiopharm Theranostics Limited	C-	61/100	—	—	—	+17.52%	$16.1M	/radx-vs-neup →
JAGX Jaguar Health Inc.	E	31/100	—	67.2%	-35.0%	-2.86%	$15.9M	/jagx-vs-neup →
AEON AEON Biopharma Inc. (Class A)	D	48/100	—	—	-35.0%	+11.36%	$17.4M	/aeon-vs-neup →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001191070

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Neuphoria Therapeutics Inc. (NEUP) reported GAAP revenue of $15.6M (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$369.6K, operating cash flow of $77.2K, and free cash flow of $77.2K (+100.5% YoY). On the balance sheet, NEUP closed FY2025 with $36.6M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-06-30	$15.6M	-$369.6K	$77.2K	$77.2K	$36.6M	—
FY2024 (FY)	2024-06-30	$0	-$15.5M	-$14.7M	-$14.7M	$18.2M	—
FY2023 (FY)	2023-06-30	$0	-$21.4M	-$14.6M	-$14.6M	—	—

3. NEUP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NEUP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Neuphoria Therapeutics Inc. (NASDAQ: NEUP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $3.06 (-8.93% 1D, market cap $16.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NEUP ranks #899 in composite RQD confidence.

How does NEUP compare to MRKR and RADX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NEUP carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -11.8%. By comparison, MRKR (Marker Therapeutics Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC -35.0%, cap $16.8M) and RADX (Radiopharm Theranostics Limited) posts a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $16.1M). Among the 5-stock peer group, NEUP leads on earnings multiple (N/A) while NEUP leads on capital efficiency (-11.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NEUP?

Per NEUP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001191070), Neuphoria Therapeutics Inc. generated $15.6M in revenue, -$369.6K in net income, and $77.2K in free cash flow against $36.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NEUP trading relative to its 50-day, 200-day, and 52-week technical levels?

NEUP last traded at $3.06 (-8.93% on volume of 70,088 shares), positioning the stock -14.29% below its 50-day simple moving average ($3.57) and -26.44% below its 200-day simple moving average ($4.16). Across its 52-week range of $3.03 to $5.53, NEUP sits at the 1.2% percentile with a 14-day RSI of 25.4 (OVERSOLD (<32)) and an implied next-earnings move of ±7.7% ($2.82 to $3.30).

NEUP Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Neuphoria Therapeutics Inc. (NEUP)?

In FY 2025 (10-K), NEUP converted $15.6M of revenue into a 52% gross margin, 0% operating margin, and $77229 in free cash flow (0.5% FCF margin).

Direct Sub-Reports: NEUP RQD Cockpit NEUP 12M Forecast NEUP Earnings & Move NEUP Dividends & DRIP NEUP Insiders & 13F NEUP Whale Options NEUP Profit Sankey NEUP News & Why